Inovio Pharmaceuticals, Inc.
$1.18
▼
-35.06%
2026-04-21 07:32:00
www.inovio.com
NCM: INO
Explore Inovio Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$96.69 M
Current Price
$1.18
52W High / Low
$2.98 / $1.03
Stock P/E
—
Book Value
$0.35
Dividend Yield
—
ROCE
-283.35%
ROE
-1.83%
Face Value
—
EPS
$-1.81
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
112
Beta
1.7
Debt / Equity
38.88
Current Ratio
1.4
Quick Ratio
1.4
Forward P/E
-1.64
Price / Sales
1,323.59
Enterprise Value
$24.09 M
EV / EBITDA
-0.28
EV / Revenue
368.71
Rating
Buy
Target Price
$6.97
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Xenon Pharmaceuticals Inc. | $57.09 | — | $5.48 B | — | -63.09% | -51.76% | $63.95 / $28.19 | $7.27 |
| 2. | MannKind Corporation | $2.92 | 135.49 | $907.36 M | — | 7.49% | -9.03% | $6.51 / $2.23 | $-0.17 |
| 3. | Celularity Inc. | $1.24 | — | $35.47 M | — | -48.8% | -232.51% | $4.35 / $1.01 | $-0.71 |
| 4. | Veru Inc. | $2.43 | — | $39 M | — | -161.13% | -60.25% | $7.4 / $2.06 | $2.31 |
| 5. | Cue Biopharma, Inc. | $0.85 | — | $82.97 M | — | -92.35% | -121.11% | $1.03 / $0.17 | $0.27 |
| 6. | Palisade Bio, Inc. | $2.5 | — | $414.71 M | — | -13.92% | -24.52% | $2.64 / $0.53 | $0.81 |
| 7. | Cognition Therapeutics, Inc. | $1.12 | — | $106.33 M | — | -70.77% | -88.59% | $3.83 / $0.22 | $0.39 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.07 M | 0.12 M | — |
| Operating Profit | -17.48 M | -21.21 M | -23.08 M | -25.05 M | -20.37 M | — |
| Net Profit | 3.76 M | -45.5 M | -23.52 M | -19.69 M | -19.38 M | — |
| EPS in Rs | 0.05 | -0.56 | -0.29 | -0.24 | -0.24 | -0.89 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.07 M | 0.22 M | 0.83 M | 10.26 M |
| Operating Profit | -86.82 M | -112.4 M | -133.43 M | -267.57 M |
| Net Profit | -84.95 M | -107.25 M | -135.12 M | -279.82 M |
| EPS in Rs | -1.04 | -1.31 | -1.66 | -3.43 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 74.31 M | 113.2 M | 170.95 M | 348.53 M |
| Total Liabilities | 50.21 M | 44.69 M | 53.6 M | 126.17 M |
| Equity | 24.1 M | 68.5 M | 117.35 M | 222.36 M |
| Current Assets | 61.12 M | 97.83 M | 153.11 M | 315.24 M |
| Current Liabilities | 43.67 M | 35.33 M | 42.57 M | 96.87 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -88.63 M | -104.08 M | -124.37 M | -216.22 M |
| Investing CF | 14.04 M | 104.07 M | 87.36 M | 109.59 M |
| Financing CF | 53.05 M | 51.48 M | 5 M | 81.84 M |
| Free CF | -88.92 M | -104.56 M | -124.69 M | -217.18 M |
| Capex | -0.29 M | -0.49 M | -0.32 M | -0.97 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -73.83% | -91.89% | — | — |
| Earnings Growth % | 20.62% | 51.71% | — | — |
| Profit Margin % | -49254.27% | -16239.87% | -2726.67% | — |
| Operating Margin % | -51616.91% | -16036.67% | -2607.35% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -47735.19% | -15671.81% | -2639.8% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-01-25 | 1:0.0833333 |